Skip to main content

Status message

Node state is: Published
Story 12 September 2023
Public

Partner call: LEAP-BIO will support you licensing assets within the biopharma industry. Apply now!

thumbnail_leap-bio.1 (1).png
Someone

LEAP-BIO, a COSME project, is opening a call for Expression of Interest concerning development of IP licensing intermediary services for early-stage assets in pharma and biotech. If your organisation has relevant assets within this industry, keep reading to know more and apply.

 

The LEAP-BIO project aims to address a lack of intermediary services towards IP licensing and exploitation of early-stage assets in key-target European regions/countries, such as Portugal, Spain, France, Italy and Belgium (Wallonia region). The goal of the LEAP-BIO project is to leverage the extensive expertise and networks of the consortium to develop an early-stage focused IP licensing intermediary service for biopharma institutes, SMEs and start-ups in the target regions. 

Under their call for Expression of Interest, the LEAP-BIO project is currently seeking applicants from key target regions , who own early-stage assets at the discovery or preclinical stage that match the licensing interests of big pharma and well-funded biotech companies. More information on the big pharma & biotech interests can be found in the “Interests from big pharma & biotech” document (download here).

 

What’s in it for you?

Applicants will gain access to a specialised free-of-charge IP licensing intermediary service, designed to facilitate the complex process of licensing assets within the biopharma industry. By applying to this call, applicants will increase their chances of securing a successful licensing deal, as their assets will be showcased to companies with matching interests. Successful applicants will also have the opportunity to receive support from LEAP-BIO during negotiations, including assistance with negotiating term-sheets.

 

Who can apply?

The assets submitted must meet the following criteria:

  • Early-stage assets (discovery and preclinical stages)
  • Ready for out-license
  • Aligned with the topics of interest listed in the pdf document “Interests from big pharma & biotech” 
  • Country / Regions: Portugal, Spain, France, Italy and Belgium (Wallonia region)

 

How to apply?

Companies interested in submitting early-stage assets should complete the Asset forms (download here) only with non-confidential information, and send it to imm-techtransfer@medicina.ulisboa.pt before the stage deadline.

Expressions of Interest (EoI) will be accepted in two independent stages.

1st stage: - CLOSED

  • Open: 17th of May (Wednesday), 9AM CET time
  • Closure: 4th of July (Tuesday), 6PM CET time

2nd stage: OPEN for applications

  • Open: 5th of September (Tuesday), 9AM CET time
  • Closure: 19th of October (Thursday), 6PM CET time

 

More information

For more details on the call for Expression of Interest, please check the “LEAP-BIO EoI” document (download here).

If you have any questions or doubts, please contact iMM’s Technology Transfer Office (imm-techtransfer@medicina.ulisboa.pt)

DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.

Please log in to see comments and contribute